Finance

Lists
600196:SHA
Shanghai Fosun Pharmaceutical (Group) Ord Shs A
CNÂ¥22.66
+1.57%
(+0.35) 1D
Oct 30, 3:00:01 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600196...
Open
CNÂ¥22.34
High
CNÂ¥23.03
Low
CNÂ¥22.10
Mkt. cap
55.37B
Avg. vol.
18.13M
Volume
19.96M
Dividend
1.72%
Quarterly dividend
CNÂ¥0.10
Ex-dividend date
Jul 27, 2026
P/E ratio
16.99
52-wk high
CNÂ¥29.68
52-wk low
CNÂ¥20.85
EPS
CNÂ¥1.33
Shares outstanding
2.01B
No. of employees
41K
Open
CNÂ¥22.34
High
CNÂ¥23.03
Low
CNÂ¥22.10
Mkt. cap
55.37B
Avg. vol.
18.13M
Volume
19.96M
Dividend
1.72%
Quarterly dividend
CNÂ¥0.10
Ex-dividend date
Jul 27, 2026
P/E ratio
16.99
52-wk high
CNÂ¥29.68
52-wk low
CNÂ¥20.85
EPS
CNÂ¥1.33
Shares outstanding
2.01B
No. of employees
41K
News stories
From web sources and news partners
Profile
Shanghai Fosun Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company. It is mostly owned by Fosun International. As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index. The company was ranked 1,840th in 2020 edition of the Forbes Global 2000, a list of top listed companies of the world. Wikipedia
About Shanghai Fosun Pharmaceutical (Group) Ord Shs A
CEOLiu Yi | Wen Deyong
Employees40.7K
Founded1994
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
12.27B
10.07B
10.37B
10.02B
Cost of goods sold
5.65B
5.07B
5.23B
5.02B
Cost of revenue
5.65B
5.07B
5.23B
5.02B
Research and development expenses
1.28B
896.79M
1.19B
1.03B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.44B
3.27B
3.35B
3.07B
Operating expense
5.92B
4.19B
4.63B
4.04B
Total operating expenses
11.57B
9.26B
9.86B
9.07B
Operating income
699.05M
813.78M
505.27M
952.46M
Other non operating income
107.33M
2.03M
-13.28M
-120.93M
EBT including unusual items
1.27B
1.36B
1.23B
1.29B
EBT excluding unusual items
1.10B
1.21B
1.07B
1.19B
Income tax expense
82.80M
277.92M
159.73M
194.01M
Effective tax rate
6.50%
20.47%
13.00%
15.01%
Other operating expenses
117.57M
19.04M
74.01M
-86.15M
Net income
847.27M
870.83M
850.64M
946.02M
Net profit margin
6.91%
8.64%
8.20%
9.44%
Earnings per share
-
-
-
-
Interest and investment income
732.13M
689.67M
938.86M
626.69M
Interest expense
-291.32M
-296.51M
-310.88M
-314.27M
Net interest expenses
440.80M
393.16M
627.98M
312.42M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.47B
1.59B
1.24B
1.73B
Gain or loss from assets sale
-69.35M
-
-195.23K
195.23K
Upcoming events
AI content may include mistakes. Learn more
Google apps